glpg management reiter detail previous announc long-term
strateg deal gilead see separ note management reiter
partner gilead intend file filgotinib eu us
top-line data filgotinib sjogren cutan lupu
erythematosu cle expect data phiii select
studi filgotinib uc avail data phiii
divers studi crohn like avail top line phi data
gener toledo compound expect addit
inform currently-undisclos toledo mechan target
indic expect management state phiib rocella trial
intend evalu glpg patient osteoarthr complet
enrol six month ahead time among trial initi
gecko phii ad mor novesa phii system sclerosi
see upcom day greater disclosur around toledo
key upcom catalyst glpg
line expect management report trelegi beat
breo/anoro miss addit detail see full summari also
note on-going arbitr therav biopharma
cover therav entitl royalti paid gsk trelegi
entitl remain net overal sale
withheld payment therav result
initi arbitr may breach oper agreement
two compani disput resolut hear commenc
juli hear expect last sever day await
commentari management matter keep trelegi royalti
payment posit likewis believ management return
payment therav biopharma withheld start
hurt report cash-flow would expect investor view
current act financi advisor galapago
galapago relat agreement enter global
collabor inc cover galapago current futur
portfolio collabor announc juli propos
transact subject requir regulatori approv customari close
condit certain element collabor subject approv
galapago sharehold galapago agre pay fee morgan stanley
servic conting upon consumm propos
transact pleas refer note end report
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
breo anoro success drive risk reward
breo anoro success drive risk reward
pt deriv dcf assum discount rate
breo anoro captur signific share market bull case
assum breo anoro characterist qd dose breo lack
ic anoro drive major share copd asthma
prescript given sluggish launch drug comfort
physician approv laba/icss see scenario unlik
model peak ww sale breo anoro
trelegi
breo anoro sluggish launch case assum breo
anoro gain modest share copd/asthma prescript model peak ww
sale breo anoro trelegi
dcf valu equiti stream royalti less net-debt
breo anoro falter commerci bear case assum breo anoro
fail gain commerci traction model ww sale breo anoro
trelegi
underweight see limit
upsid valuat impli
potenti gsk consolid royalti
interest breo/anoro
launch breo anoro
sluggish far
breo qd dose potenti complianc
advantag howev top-line result
breo phiii trial suggest profil similar
patient switch approv laba/icss
compet least initi
laba/ class mean growth anoro
expect maba/tripl combo
cannib sale breo anoro
patient need come laba/
lama/laba take one drug
key driver model includ
royalti breo launch
anoro launch
risk achiev price
breo and/or anoro may sell better
compani may potenti
busi develop transact may
inform opinion research prepar co llc and/or and/or morgan
stanley mexico de bolsa de and/or canada limit use disclosur section includ morgan
stanley co llc mexico de bolsa de canada limit affili
necessari
import disclosur stock price chart equiti rate histori regard compani subject report pleas see morgan
stanley research disclosur websit www morganstanley com/researchdisclosur contact invest repres
research broadway attent research manag new york ny usa
valuat methodolog risk associ recommend rate price target referenc research report pleas contact client
support follow us/canada hong kong latin america london
singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
follow analyst herebi certifi view compani secur discuss report accur express
receiv receiv direct indirect compens exchang express specif recommend view report matthew
unless otherwis state individu list cover page report research analyst
morgan stanley research publish accord conflict manag polici avail
www morganstanley com/institutional/research/conflictpolici portugues version polici found www morganstanley com br
import us regulatori disclosur subject compani
june benefici own class common equiti secur follow compani cover morgan
within last month manag co-manag public offer offer secur alector inc argenx se avrobio inc
within last month receiv compens invest bank servic alector inc argenx se avrobio inc
next month expect receiv intend seek compens invest bank servic akebia
within last month receiv compens product servic invest bank servic amgen inc
within last month provid provid invest bank servic invest bank client relationship
follow compani alder biopharmaceut inc alector inc alnylam
within last month either provid provid non-invest bank securities-rel servic and/or past
enter agreement provid servic client relationship follow compani amgen inc beigen ltd biogen inc biomarin
 co llc make market secur alder biopharmaceut inc alector inc
equiti research analyst strategist princip respons prepar research receiv compens base upon
variou factor includ qualiti research investor client feedback stock pick competit factor firm revenu overal invest bank
revenu equiti research analyst strategist compens link invest bank capit market transact perform morgan
stanley profit revenu particular trade desk
affili busi relat companies/instru cover research includ market make provid
liquid fund manag commerci bank extens credit invest servic invest bank sell buy
custom securities/instru compani cover research princip basi may posit debt
compani instrument discuss report trade may trade princip debt secur relat deriv
subject debt research report
certain disclosur list also complianc applic regul non-u jurisdict
use rel rate system use term overweight equal-weight not-rat underweight see definit morgan
stanley assign rate buy hold sell stock cover overweight equal-weight not-rat underweight equival
buy hold sell investor care read definit rate use morgan stanley research addit sinc morgan stanley research
contain complet inform concern analyst view investor care read morgan stanley research entireti infer
content rate alon case rate research use reli upon invest advic investor decis buy sell
stock depend individu circumst investor exist hold consider
june
stock rate describ appli fundament equiti research appli debt research produc firm
disclosur purpos accord nasd nyse requir includ categori head buy hold sell alongsid
rate overweight equal-weight not-rat underweight assign rate buy hold sell stock cover
overweight equal-weight not-rat underweight equival buy hold sell repres recommend rel weight see
definit satisfi regulatori requir correspond overweight posit stock rate buy recommend correspond
equal-weight not-rat hold underweight sell recommend respect
data includ common stock adr current assign rate invest bank client compani receiv invest
bank compens last month due round decim percentag provid total column may add exactli
overweight stock total return expect exceed averag total return analyst industri industri team coverag univers
risk-adjust basi next month
equal-weight stock total return expect line averag total return analyst industri industri team coverag univers
risk-adjust basi next month
not-rat nr current analyst adequ convict stock total return rel averag total return analyst
industri industri team coverag univers risk-adjust basi next month
underweight stock total return expect averag total return analyst industri industri team coverag univers
risk-adjust basi next month
unless otherwis specifi time frame price target includ morgan stanley research month
attract analyst expect perform industri coverag univers next month attract vs relev broad
market benchmark indic
in-lin analyst expect perform industri coverag univers next month line relev broad market
benchmark indic
cautiou analyst view perform industri coverag univers next month caution vs relev broad market
benchmark indic
benchmark region follow north america latin america relev countri index latin america index europ
europ japan topix asia relev countri index sub-region index ac asia pacif ex japan index
stock price price target rate histori rate definit
import disclosur morgan stanley smith barney llc custom
